PL3419622T3 - Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny - Google Patents
Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidynyInfo
- Publication number
- PL3419622T3 PL3419622T3 PL17757261.7T PL17757261T PL3419622T3 PL 3419622 T3 PL3419622 T3 PL 3419622T3 PL 17757261 T PL17757261 T PL 17757261T PL 3419622 T3 PL3419622 T3 PL 3419622T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- treatment
- eye disease
- neurodegenerative eye
- neurodegenerative
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299290P | 2016-02-24 | 2016-02-24 | |
| PCT/US2017/019266 WO2017147366A1 (en) | 2016-02-24 | 2017-02-24 | Treatment of neurodegenerative eye disease using pridopidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3419622T3 true PL3419622T3 (pl) | 2024-07-08 |
Family
ID=59686581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17757261.7T PL3419622T3 (pl) | 2016-02-24 | 2017-02-24 | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11738012B2 (pl) |
| EP (1) | EP3419622B1 (pl) |
| JP (1) | JP7034488B2 (pl) |
| AU (1) | AU2017223838B2 (pl) |
| CA (1) | CA3015512C (pl) |
| DK (1) | DK3419622T3 (pl) |
| PL (1) | PL3419622T3 (pl) |
| WO (1) | WO2017147366A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| WO2023062632A1 (en) * | 2021-10-11 | 2023-04-20 | Prilenia Neurotherapeutics Ltd. | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease |
| CN109923102B (zh) | 2016-08-24 | 2022-11-15 | 普瑞尼亚神经治疗有限公司 | 普利多匹定用于治疗功能下降的用途 |
| JP7278210B2 (ja) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2020243692B2 (en) * | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| IL134241A (en) * | 2000-01-27 | 2006-06-11 | Finetech Pharmaceutical Ltd | Process for the preparation of latanoprost |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| JP5393654B2 (ja) | 2007-04-12 | 2014-01-22 | イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体 |
| CA2688439A1 (en) | 2007-05-31 | 2008-12-11 | Joseph Weinstock | Treatment of age-related macular degeneration |
| AU2008296908B2 (en) * | 2007-09-05 | 2014-01-09 | Teva Pharmaceutical Industries, Ltd. | Method of treating glaucoma using rasagiline |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| ES2639052T3 (es) | 2011-09-07 | 2017-10-25 | Teva Pharmaceuticals International Gmbh | Forma polimórfica de hidrocloruro de pridopidina |
| UY34503A (es) * | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| WO2013152105A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| CN104768545A (zh) | 2012-09-27 | 2015-07-08 | 泰华制药工业有限公司 | 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
| EP4049657A1 (en) | 2014-01-22 | 2022-08-31 | Prilenia Neurotherapeutics Ltd. | Modified release formulations of pridopidine |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| WO2016138130A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| KR20200031446A (ko) | 2018-09-14 | 2020-03-24 | 삼성전자주식회사 | 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치 |
-
2017
- 2017-02-24 EP EP17757261.7A patent/EP3419622B1/en active Active
- 2017-02-24 WO PCT/US2017/019266 patent/WO2017147366A1/en active Application Filing
- 2017-02-24 US US16/078,929 patent/US11738012B2/en active Active
- 2017-02-24 CA CA3015512A patent/CA3015512C/en active Active
- 2017-02-24 AU AU2017223838A patent/AU2017223838B2/en active Active
- 2017-02-24 PL PL17757261.7T patent/PL3419622T3/pl unknown
- 2017-02-24 DK DK17757261.7T patent/DK3419622T3/da active
- 2017-02-24 JP JP2018544853A patent/JP7034488B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7034488B2 (ja) | 2022-03-14 |
| AU2017223838A1 (en) | 2018-09-06 |
| US11738012B2 (en) | 2023-08-29 |
| EP3419622A4 (en) | 2019-07-10 |
| US20190046516A1 (en) | 2019-02-14 |
| CA3015512A1 (en) | 2017-08-31 |
| WO2017147366A1 (en) | 2017-08-31 |
| AU2017223838B2 (en) | 2022-09-29 |
| DK3419622T3 (da) | 2024-06-03 |
| JP2019507758A (ja) | 2019-03-22 |
| EP3419622A1 (en) | 2019-01-02 |
| EP3419622B1 (en) | 2024-03-06 |
| CA3015512C (en) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245078A1 (zh) | 治療神經退行性疾病的方法 | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| PL3419622T3 (pl) | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| GB201608046D0 (en) | Treatment of complement-mediated disorders | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL267229A (en) | Methods of treating ocular disorders | |
| EP3157631A4 (en) | Neurodegenerative disease treatment | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3145532A4 (en) | Individualized treatment of eye disease | |
| IL259381B (en) | Miravegron for the treatment of retinal diseases | |
| EP3474876A4 (en) | TREATMENT OF MORBUS CANAVAN | |
| GB201411616D0 (en) | Diagnosis and treatment of neurodegenerative disorders | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| IL263837A (en) | Treatment of ocular disease | |
| PT3903774T (pt) | N,n-bis-2-mercaptoetilisoftalamida para o tratamento de doenças neurodegenerativas | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201610938D0 (en) | Treatment of ocular disease |